Invetx, a pioneer in protein-based therapeutics for animal health, announced today that it has raised an additional $10.25 million in its Series A financing, bringing the total amount to $25.5 million. New investors include Casdin Capital and funds managed by Tekla Capital Management, LLC, joining existing lead investor Anterra Capital, as well as strategic investors AbCellera Biologics and WuXi Biologics. In addition, Invetx announced the appointments of Bill Brondyk, PhD, as chief scientific officer and Colin Giles, PhD, as chief development officer to its executive team.